Valneva (VALN) has released an update.
Valneva SE has announced a significant advancement with the European Medicines Agency’s positive opinion on its chikungunya vaccine, IXCHIQ®, which may become the first such vaccine approved in the EU. A final decision by the European Commission is expected in Q3 2024, following the recent U.S. approval. The vaccine shows a high seroresponse rate and is part of Valneva’s broader effort to address infectious diseases with unmet medical needs.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
